The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Renal function in gout: long-term treatment effects of febuxostat.
Andrew Whelton; Patricia A Macdonald; Lin Zhao; Barbara Hunt; Lhanoo Gunawardhana (Profiled Author: Andrew Whelton)
Universal Clinical Research Center, Inc., 1737 Beaver Brook Lane, Hunt Valley, MD 21030-1603, USA. firstname.lastname@example.org
Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases 2011;17(1):7-13.
BACKGROUND: The association between hyperuricemia, gout, and impaired renal function has long been recognized. Recent data provide evidence for the causal relationship between elevated serum urate (sUA) and renal changes, leading to declines in glomerular filtration rates. In healthy adults, glomerular filtration rate wanes with age. Urate-lowering therapy (ULT) with allopurinol has been shown to stabilize or reverse this. OBJECTIVE: Here we examine the long-term effects of ULT with febuxostat on estimated glomerular filtration rate (eGFR). METHODS: This is a post hoc analysis of the Febuxostat Open-label Clinical trial of Urate-lowering efficacy and Safety study, during which 116 hyperuricemic gout subjects received daily doses of febuxostat (40, 80, or 120 mg) for up to 5 years. sUA concentrations and eGFR were assessed regularly. Results were stratified by mean change in sUA from baseline. Mathematical modeling was used to predict the effect of sUA reduction on eGFR. RESULTS: Maintenance or improvement in eGFR was inversely correlated with the quantitative reduction in sUA from baseline. For every 1 mg/dL decrease in sUA, the model projected an expected improvement in eGFR of 1 mL/min from the untreated value. CONCLUSION: Individuals with the greatest reductions in sUA may experience reduced rates of renal deterioration or even stabilization of renal function. Further studies examining the impact of long-term ULT on renal function in hyperuricemic gout patients are needed to both confirm our results and verify if improvements in renal function are feasible in such patients.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Andrew Whelton; Patricia A MacDonald; Solomon Chefo; Lhanoo GunawardhanaPostgraduate medicine 2013;125(1):106-14.
Stephen P Juraschek; Lara C Kovell; Edgar R Miller; Allan C GelberPloS one 2013;8(2):e56546.
Allan C GelberThe New England journal of medicine 2006;354(14):1532-3; author reply 1532-3.
Appears in this Publication
Author of this Publication